Saturday, November 14, 2026

Apollo Drops 9% as Global Private Equity Pivots to Fee-Based Models

Apollo Global Management fell 9% amid private credit concerns and S&P 500 correction fears, accelerating a global shift in private equity toward stable fee income. Firms from North America to Europe are building diversified platforms to reduce dependence on volatile deal exits as elevated interest rates stress traditional buyout models.

From our archive, published before source-traceability. How we work

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
Apollo Drops 9% as Global Private Equity Pivots to Fee-Based Models
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Apollo Global Management shares fell 9% as private credit stress and equity correction fears drive a worldwide restructuring of the private equity industry toward fee-based revenue models.

Hamilton Lane is expanding beyond buyouts into venture capital, secondaries, and infrastructure to generate stable management fees across market cycles. The shift mirrors moves by European and Asian PE firms seeking revenue sources independent of deal timing as interest rates remain elevated globally.

Canadian firm Onex completed its acquisition of Convex, establishing a partnership with AIG that CEO Bobby Le Blanc called "a pivotal moment that meaningfully enhances our growth prospects." The deal positions Onex to capture insurance-linked investment flows while diversifying beyond traditional North American buyouts.

The transformation reflects mounting pressure across international markets. Private credit shows stress in both US and European portfolios, while equity valuations face correction risks that threaten exit opportunities from London to Singapore.

Firms globally are prioritizing permanent capital vehicles, infrastructure funds, and credit platforms that generate predictable management fees rather than cyclical carried interest. This model provides steadier earnings during downturns when deal flow freezes across regions.

European PE firm Audacia raised €8M in a fully subscribed capital increase at €4.05 per share, demonstrating continued investor appetite despite volatility. The French firm has deployed over €1B across 400+ companies, showing smaller managers can attract capital with focused strategies.

The diversification drive aims to reduce dependence on exit timing and valuation multiples that vary by geography and market conditions. Firms building scaled asset management platforms can weather cycles through fee income while maintaining optionality for performance gains when conditions improve.

The trend accelerates as PE firms compete with traditional asset managers like BlackRock and institutional investors reallocate capital across North America, Europe, and Asia-Pacific alternatives platforms.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: Strong
  1. [1]Press releaseGlobeNewswire· February 9, 2026
    Augmentation de capital de 8 M€ réalisée avec succès
  2. [2]Press releaseGlobeNewswire· February 9, 2026
    dsm-firmenich announces agreement to divest Animal Nutrition & Health to CVC Capital Partners
  3. [3]News articleYahoo Finance· February 12, 2026
    Franklin Lexington Private Equities Secondaries Strategy Exceeds $3.5 Billion in Assets Under Management Globally Within First Year
  4. [4]News articleYahoo Finance· February 3, 2026
    KKR-Led Consortium with Singtel Group to Fully Acquire ST Telemedia Global Data Centres at S$13.8 Billion Enterprise Value
  5. [5]News articleYahoo Finance· February 25, 2026
    Oak-Eagle AcquireCo, Inc. Announces Pricing Terms for the Previously Announced Tender Offers and Consent Solicitations for Any and All of Electronic Arts Inc.'s 1.850% Senior Notes Due 2031 and 2.950% Senior Notes Due 2051
  6. [6]News articleYahoo Finance· February 20, 2026
    Onex Reports Fourth Quarter and Full Year 2025 Results
  7. [7]Press releaseGlobeNewswire· February 9, 2026
    Successful €8m rights issue
  8. [8]Press releaseGlobeNewswire· February 26, 2026
    Annual Results 2025: clear second half improvement, restructuring measures show first results
  9. [9]Press releaseGlobeNewswire· November 13, 2025
    Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
  10. [10]News articleYahoo Finance· February 23, 2026
    Keurig Dr Pepper Announces Updated Financing Plan for JDE Peet's Acquisition
  11. [11]News articleYahoo Finance· December 16, 2025
    Shell invests in Kaikias waterflood to unlock production in Gulf of America
  12. [12]News articleYahoo Finance· February 27, 2026
    Stock market today: Dow, S&P 500, Nasdaq sink after hot PPI inflation print, indexes on track for monthly losses

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,580 source documents archived
Query this data → isubstrate.com